Metabolomics in multiple sclerosis

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system with inflammatory and degenerative components. The cause of MS remains unknown although genetic and environmental factors appear to play a role in its etiopathogenesis. Metabolomics is a new €omics€ technology that aims at measuring small molecules in various biological matrices and can provide information that is not readily obtained from genomics, transcriptomics, or proteomics. Currently, several different analytical platforms exist for metabolomics, and both untargeted and targeted approaches are being employed. Methods of analysis of metabolomics data are also being developed and no consensus currently exists on the optimal approach to analysis and interpretation of these data. Metabolomics has the potential to provide putative biomarkers, insights into the pathophysiology of the disease, and to aid in precision medicine for patients with MS.

Original languageEnglish (US)
Pages (from-to)451-460
Number of pages10
JournalMultiple Sclerosis
Volume22
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Metabolomics
Multiple Sclerosis
Precision Medicine
Demyelinating Diseases
Genomics
Proteomics
Central Nervous System
Biomarkers
Technology

Keywords

  • biomarkers
  • mass spectrometry
  • Metabolomics
  • multiple sclerosis
  • nuclear magnetic resonance

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Metabolomics in multiple sclerosis. / Bhargava, Pavan; Calabresi, Peter.

In: Multiple Sclerosis, Vol. 22, No. 4, 01.04.2016, p. 451-460.

Research output: Contribution to journalArticle

@article{e3fb59bea2c840059e82f7a904fdb244,
title = "Metabolomics in multiple sclerosis",
abstract = "Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system with inflammatory and degenerative components. The cause of MS remains unknown although genetic and environmental factors appear to play a role in its etiopathogenesis. Metabolomics is a new €omics€ technology that aims at measuring small molecules in various biological matrices and can provide information that is not readily obtained from genomics, transcriptomics, or proteomics. Currently, several different analytical platforms exist for metabolomics, and both untargeted and targeted approaches are being employed. Methods of analysis of metabolomics data are also being developed and no consensus currently exists on the optimal approach to analysis and interpretation of these data. Metabolomics has the potential to provide putative biomarkers, insights into the pathophysiology of the disease, and to aid in precision medicine for patients with MS.",
keywords = "biomarkers, mass spectrometry, Metabolomics, multiple sclerosis, nuclear magnetic resonance",
author = "Pavan Bhargava and Peter Calabresi",
year = "2016",
month = "4",
day = "1",
doi = "10.1177/1352458515622827",
language = "English (US)",
volume = "22",
pages = "451--460",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Metabolomics in multiple sclerosis

AU - Bhargava, Pavan

AU - Calabresi, Peter

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system with inflammatory and degenerative components. The cause of MS remains unknown although genetic and environmental factors appear to play a role in its etiopathogenesis. Metabolomics is a new €omics€ technology that aims at measuring small molecules in various biological matrices and can provide information that is not readily obtained from genomics, transcriptomics, or proteomics. Currently, several different analytical platforms exist for metabolomics, and both untargeted and targeted approaches are being employed. Methods of analysis of metabolomics data are also being developed and no consensus currently exists on the optimal approach to analysis and interpretation of these data. Metabolomics has the potential to provide putative biomarkers, insights into the pathophysiology of the disease, and to aid in precision medicine for patients with MS.

AB - Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system with inflammatory and degenerative components. The cause of MS remains unknown although genetic and environmental factors appear to play a role in its etiopathogenesis. Metabolomics is a new €omics€ technology that aims at measuring small molecules in various biological matrices and can provide information that is not readily obtained from genomics, transcriptomics, or proteomics. Currently, several different analytical platforms exist for metabolomics, and both untargeted and targeted approaches are being employed. Methods of analysis of metabolomics data are also being developed and no consensus currently exists on the optimal approach to analysis and interpretation of these data. Metabolomics has the potential to provide putative biomarkers, insights into the pathophysiology of the disease, and to aid in precision medicine for patients with MS.

KW - biomarkers

KW - mass spectrometry

KW - Metabolomics

KW - multiple sclerosis

KW - nuclear magnetic resonance

UR - http://www.scopus.com/inward/record.url?scp=84962602520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962602520&partnerID=8YFLogxK

U2 - 10.1177/1352458515622827

DO - 10.1177/1352458515622827

M3 - Article

VL - 22

SP - 451

EP - 460

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 4

ER -